Recursion Pharmaceuticals Inc - Class A – Quartalsfinanzdaten (NASDAQ:RXRX)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -115.43 M-131.96 M-76.42 M-117.36 M-46.07 M -371.81 M Mittelzufluss aus Investitionstätigkeit 275.46 M-7.27 M-5.81 M-2.55 M-1.24 M -16.87 M Zahlungsströme aus der Finanzierungstätigkeit 10.64 M40.53 M97.66 M251.34 M132.01 M 521.53 M Freier Cashflow -117.08 M-133.79 M-79.57 M-117.6 M-47.32 M -378.28 M

Recursion Pharmaceuticals Inc - Class A

Recursion Pharmaceuticals is a clinical-stage biotechnology company that focuses on mapping and decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering. The company is based in Salt Lake City, Utah. It was founded by Chris Gibson, Dean Li and Blake Borgeson.

RXRX

Financials

Recursion Pharmaceuticals Inc - Class A

Nachrichten

Recursion-CEO erläutert KI-Strategie zur Beschleunigung der Medikamentenentwicklung

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

Citeline und Recursion vertiefen Partnerschaft für datengestützte Medikamentenentwicklung

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

Aktie von Recursion Pharmaceuticals erreicht neues 52-Wochen-Tief

Bitcoin Skids, $14 Bil In Options Due; Cathie Wood Raises Cash

Cathie Wood: ARK Invest stößt Meta und Nvidia ab, kauft bei Tempus AI zu

Insider-Verkauf bei Recursion Pharmaceuticals: Director stößt Aktienpaket ab

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Recursion Pharma: CFO verkauft Aktien im Wert von rund 27.000 $

Rose the dog might have just heralded the age of programmable medicine — and here are the stocks that benefit

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know